ET-01 in Subjects With Lateral Canthal Lines, LCL-208
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 25 - 65 |
Updated: | 2/17/2019 |
Start Date: | October 16, 2018 |
End Date: | August 2019 |
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A,
topical, in lateral canthal lines (LCL).
topical, in lateral canthal lines (LCL).
This product is being tested for its ability to reduce lateral canthal lines, also known as
Crow's Feet.
Crow's Feet.
Inclusion Criteria:
- females 25 - 65 years of age
- minimal to moderate Crow's Feet wrinkles at rest
- moderate to severe Crow's Feet on contraction
- adequate vision to assess facial wrinkles in a mirror
- willingness to refrain from products affecting skin remodeling
- female subjects must be not pregnant and non-lactating
- subjects should be in good general health
Exclusion Criteria:
- history of adverse reactions to any prior botulinum toxin treatments
- history of vaccination or non-response to any prior botulinum toxin treatments
- botulinum toxin treatment in the prior 6 months
- present or history of neuromuscular disease, eyelid ptosis, muscle weakness,
paralysis, or "dry eye"
- history of peri-ocular surgery, brow lift or related procedures
- procedures affecting the lateral canthal region in the prior 12 months
- application of topical prescription medication to the treatment area
- female subjects who are pregnant or are nursing a child
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials